Source:http://linkedlifedata.com/resource/pubmed/id/20673002
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2010-8-5
|
pubmed:abstractText |
The efficacy of tenofovir disoproxil fumarate (TDF) as part of combination antiretroviral treatment (ART) has been demonstrated in several randomized, controlled trials. However, an increasing number of case reports suggest that TDF use may be associated with significant nephrotoxicity. Our objective was to determine the renal safety of TDF-containing ART regimens for HIV-infected individuals.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
1537-6591
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:day |
1
|
pubmed:volume |
51
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
496-505
|
pubmed:meshHeading | |
pubmed:year |
2010
|
pubmed:articleTitle |
Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.
|
pubmed:affiliation |
Department of Medicine, University of Alberta, Edmonton, Canada.
|
pubmed:publicationType |
Journal Article,
Review,
Meta-Analysis
|